ReviewGlutamatergic medications for the treatment of drug and behavioral addictions
Research Highlights
► Glutamate plays a critical role in both drug and behavioral addictions. ► Medications with glutamatergic actions show promise for addiction treatment. ► Mechanisms of action and clinical efficacy of glutamatergic medications are reviewed.
Introduction
Drug addiction, defined by the American Psychiatric Association as substance dependence (American Psychiatric Association, 2002), has numerous maladaptive psychological and behavioral manifestations including: loss of control over drug intake, taking drugs in greater quantities than intended, repeated unsuccessful attempts at quitting or reducing drug use, continued drug use despite negative consequences, and the emergence of drug-specific symptoms of tolerance and/or withdrawal. In addition to numerous intangible humanistic factors such as the disruption of families and interpersonal relationships, social dysfunction, and loss of life, the socioeconomic burden that drug addiction places on society is enormous (Cartwright, 2008, Gilson and Kreis, 2009, Malliarakis and Lucey, 2007, Rehm et al., 2009, Spanagel, 2009, Thavorncharoensap et al., 2009). In recent years it has become evident that the neural substrates underlying addiction to drugs of abuse overlap considerably with those of non-drug “behavioral” addictions (i.e., pathological gambling, pornography/internet addiction, etc.) (Grant et al., 2010a).
To date, medications that have been developed to aid in the treatment of addictive disorders have shown only moderate success. Known barriers that compromise the efficacy of medication-based approaches to treatment to addiction disorders include poor medication compliance, adverse side effects, safety issues, variable medication responses within treatment groups, poor integration of medication management into psychosocial or cognitive-behavioral therapies, inaccessibility to medications or adequate health care, and relapse following discontinuation of the therapeutic medication (Koob et al., 2009, Montoya and Vocci, 2008, O'Brien, 2008, Ross and Peselow, 2009, Zahm, 2010). While numerous medications of various classes that have been approved for other medical conditions are currently being investigated as potential aids in the treatment of addictive disorders, the only medications approved specifically for the treatment thus far in the United States are varenicline, buproprion, and nicotine replacement therapies for smoking cessation, long-acting opioids (i.e., methadone or buprenorphine) for opiate dependence, and disulfiram, naltrexone, and acamprosate for alcohol dependence. No medications to aid in the treatment of addiction to cocaine, methamphetamine, or marijuana are currently approved, nor are any approved for the treatment of behavioral addictions.
The purpose of the present review is to provide a summary of the pharmacological mechanisms of action and general clinical efficacy of medications acting on glutamatergic transmission in the treatment of addictive disorders. These medications include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. It should be noted that many of these medications have mechanisms of action that include multiple neurotransmitter systems, and perhaps with the exception of d-cycloserine, none is known to selectively target glutamatergic transmission or specific glutamate receptors. However, there is a strong body of preclinical evidence arising from over two decades of animal studies suggesting a critical role for glutamate transmission and glutamate receptors in drug reward, reinforcement, and relapse (Bird and Lawrence, 2009, Bowers et al., 2010, Gass and Olive, 2008, Kalivas et al., 2009, Moussawi and Kalivas, 2010, Olive, 2009, Olive, 2010, Reissner and Kalivas, 2010, Tzschentke and Schmidt, 2003, Uys and LaLumiere, 2008). For an overview of glutamatergic transmission and glutamate receptors, the reader is referred to the review by Sanacora in the current issue (publisher – please insert correct page numbers here). In addition, the small but growing body of literature on the use of these medications to treat behavioral addictions such as compulsive gambling, and studies on this topic will also be reviewed.
Section snippets
Mechanism of action
Acamprosate (calcium acetylhomotaurine) is derived from homotaurine, a nonspecific γ-aminobutyric acid (GABA) agonist. The molecule is N-acetylated to facilitate penetration across the blood–brain barrier, and is formulated as a calcium salt to increase absorption of the compound from the gastrointestinal tract. Despite these chemical modifications, its overall bioavailability remains poor (i.e., < 20%) and requires doses in the range of 2–3 g per day to demonstrate efficacy. Many pharmacological
Summary and conclusions
With regards to the eight medications reviewed here that possess a glutamatergic mechanism of action (acamprosate, NAC, DCS, gabapentin, lamotrigine, memantine, modafinil, and topiramate), we conclude that NAC, modafinil, and topiramate have the most well-documented and greatest potential for use in the treatment of drug and behavioral addictions. Certainly any of the medications reviewed here will not be a panacea for all addictions, but more likely an effective pharmacological aid to standard
Acknowledgments
The authors would like to thank Katie Ris-Vicari for assistance with the generation of the artwork. This work was supported by NIH grants DA024355, DA025606, and AA013852 (MFO).
References (203)
- et al.
Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats
Brain Res
(2004) - et al.
Modafinil for the treatment of cocaine dependence
Drug Alcohol Depend
(2009) - et al.
The acute effects of gabapentin in combination with alcohol in heavy drinkers
Drug Alcohol Depend
(2006) - et al.
A randomized placebo-controlled trial of gabapentin for cocaine dependence
Drug Alcohol Depend
(2006) - et al.
d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference
Behav Brain Res
(2006) - et al.
AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future
Neuron
(2010) - et al.
Treatment of alcohol withdrawal with gabapentin
Prog Neuropsychopharmacol Biol Psychiatry
(2002) - et al.
Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study
J Affect Disord
(2006) Economic costs of drug abuse: financial, cost of illness, and services
J Subst Abuse Treat
(2008)- et al.
The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro
Neuropharmacology
(2000)
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study
Drug Alcohol Depend
Effects of D-cycloserine on extinction: translation from preclinical to clinical work
Biol Psychiatry
Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
Neurosci Lett
Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis
Cell
The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission
Neurosci Lett
The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade
Neuropsychopharmacology
Glutamatergic substrates of drug addiction and alcoholism
Biochem Pharmacol
Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients
Drug Alcohol Depend
N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study
Biol Psychiatry
Smoked cocaine discrimination in humans: effects of gabapentin
Drug Alcohol Depend
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
Drug Alcohol Depend
Glutamate transmission in addiction
Neuropharmacology
Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist
Neuropharmacology
A pilot trial of topiramate for the treatment of cocaine dependence
Drug Alcohol Depend
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence
Addict Behav
A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence
Addict Behav
Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking
Neuroscience
Glutamate and reinstatement
Curr Opin Pharmacol
The role of cystine-glutamate exchange in nicotine dependence in rats and humans
Biol Psychiatry
Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking
Biol Psychiatry
Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex
Brain Res
Topiramate prevents ecstasy consumption: a case report
Fundam Clin Pharmacol
Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex
Alcohol Clin Exp Res
Repeated N-acetylcysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans
Neuropsychopharmacology
Dopamine transporter-related effects of modafinil in rhesus monkeys
Psychopharmacology
Oral topiramate effective for alcoholism
J Fam Pract
Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation
Addiction
Combined pharmacotherapies and behavioral interventions for alcohol dependence — the COMBINE study: a randomized controlled trial
JAMA
Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report
J Med Case Reports
Memantine for alcohol dependence: an open-label pilot study
Addict Disord Their Treat
The origin and neuronal function of in vivo nonsynaptic glutamate
J Neurosci
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse
Nat Neurosci
A systematic review of modafinil: potential clinical uses and mechanisms of action
J Clin Psychiatry
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Addiction
A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence
Addiction
Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting
CNS Spectr
Acamprosate enhances N-methyl-d-apartate receptor-mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons
Alcohol Clin Exp Res
Group I metabotropic glutamate receptors: involvement in drug-seeking and drug-induced plasticity
Curr Mol Pharmacol
Acute effects of memantine in combination with alcohol in moderate drinkers
Psychopharmacology
Cited by (136)
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
2023, International Review of NeurobiologyN-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials
2022, Addictive Behaviorsm-CF<inf>3</inf>-substituted diphenyl diselenide attenuates all phases of morphine-induced behavioral locomotor sensitization in mice
2022, Journal of Trace Elements in Medicine and BiologyMechanistic insights into the efficacy of memantine in treating certain drug addictions
2021, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :This glutamatergic homeostasis is disrupted differently during different stages of drug addiction (Koob and Volkow, 2010). For instance, the use of cocaine, nicotine, or low doses of alcohol causes an increase in synaptic glutamate and an inhibition of NMDA function; conversely, the use of opiates or high doses of alcohol causes a reduction in glutamate and an upregulation in NMDA function in certain brain regions (reviewed in Olive et al., 2012a). In contrast, withdrawal from alcohol is associated with a marked increase in synaptic glutamate, possibly due to reduced glutamate uptake (Abulseoud et al., 2014).
Mitochondrial dysfunction and affective disorders: Focus on diet, exercise, and aging
2021, Mitochondrial Dysfunction and Nanotherapeutics: Aging, Diseases, and Nanotechnology-Related Strategies in Mitochondrial Medicine